Based on these notions, and as GSK3β represents a crucial converging point for multiple pathways that are deregulated in CLL, it is conceivable that GSK3β is a player of the network regulating NOTCH1 activation in CLL with potential for drug targeting. Here, GSK3B is linked to B-cell chronic lymphocytic leukemia.